Julie Wolf

1.2k total citations
18 papers, 923 citations indexed

About

Julie Wolf is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Julie Wolf has authored 18 papers receiving a total of 923 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 5 papers in Molecular Biology. Recurrent topics in Julie Wolf's work include Lung Cancer Treatments and Mutations (9 papers), Pancreatic and Hepatic Oncology Research (7 papers) and Colorectal Cancer Treatments and Studies (4 papers). Julie Wolf is often cited by papers focused on Lung Cancer Treatments and Mutations (9 papers), Pancreatic and Hepatic Oncology Research (7 papers) and Colorectal Cancer Treatments and Studies (4 papers). Julie Wolf collaborates with scholars based in United States, United Kingdom and Canada. Julie Wolf's co-authors include Marta Hamilton, Karsten Witt, Gary M. Clark, Jason Rusk, Pablo J. Cagnoni, Shannon E. Beard, Daniel W. Drolet, Philip M. Zack, Raymond A. Bendele and Ashok Rakhit and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and European Journal of Cancer.

In The Last Decade

Julie Wolf

18 papers receiving 890 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Julie Wolf United States 14 495 380 335 80 67 18 923
Yoshihiro Hashimoto Japan 17 250 0.5× 228 0.6× 593 1.8× 106 1.3× 147 2.2× 64 1.2k
Valentina Rossi Italy 15 239 0.5× 135 0.4× 397 1.2× 73 0.9× 27 0.4× 26 773
H Harvey United States 11 532 1.1× 108 0.3× 213 0.6× 119 1.5× 285 4.3× 18 840
Renato V. La Rocca United States 16 335 0.7× 362 1.0× 345 1.0× 205 2.6× 36 0.5× 24 1.2k
Ritva Valavaara Finland 14 293 0.6× 134 0.4× 126 0.4× 223 2.8× 117 1.7× 29 900
Shinji Kikuchi Japan 13 178 0.4× 178 0.5× 295 0.9× 88 1.1× 64 1.0× 56 791
Rosemary Chester United Kingdom 6 366 0.7× 267 0.7× 385 1.1× 155 1.9× 42 0.6× 11 851
Christopher S. Hong United States 19 191 0.4× 240 0.6× 514 1.5× 254 3.2× 57 0.9× 89 1.3k
Rogelio Palomino‐Morales Spain 19 197 0.4× 101 0.3× 396 1.2× 114 1.4× 35 0.5× 54 1.1k
Gunhild Keller Germany 21 357 0.7× 186 0.5× 555 1.7× 52 0.7× 64 1.0× 45 1.6k

Countries citing papers authored by Julie Wolf

Since Specialization
Citations

This map shows the geographic impact of Julie Wolf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julie Wolf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julie Wolf more than expected).

Fields of papers citing papers by Julie Wolf

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julie Wolf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julie Wolf. The network helps show where Julie Wolf may publish in the future.

Co-authorship network of co-authors of Julie Wolf

This figure shows the co-authorship network connecting the top 25 collaborators of Julie Wolf. A scholar is included among the top collaborators of Julie Wolf based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julie Wolf. Julie Wolf is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
O’Reilly, Eileen M., Devalingam Mahalingam, Tanios Bekaii‐Saab, et al.. (2020). Randomised phase II trial of gemcitabine and nab-paclitaxel with necuparanib or placebo in untreated metastatic pancreas ductal adenocarcinoma. European Journal of Cancer. 132. 112–121. 27 indexed citations
2.
3.
O’Reilly, Eileen M., Devalingam Mahalingam, James Roach, et al.. (2017). Necuparanib combined with nab-paclitaxel + gemcitabine in patients with metastatic pancreatic cancer: Phase 2 results.. Journal of Clinical Oncology. 35(4_suppl). 370–370. 5 indexed citations
4.
O’Reilly, Eileen M., Devalingam Mahalingam, James Roach, et al.. (2016). Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of necuparanib combined with nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer: Updated phase 1 results.. Journal of Clinical Oncology. 34(15_suppl). 4117–4117. 2 indexed citations
5.
O’Reilly, Eileen M., Devalingam Mahalingam, James Roach, et al.. (2015). Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of necuparanib combined with nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer: Phase 1 results.. Journal of Clinical Oncology. 33(15_suppl). 4114–4114. 3 indexed citations
6.
Hamilton, Marta, Julie Wolf, Daniel W. Drolet, et al.. (2014). The effect of rifampicin, a prototypical CYP3A4 inducer, on erlotinib pharmacokinetics in healthy subjects. Cancer Chemotherapy and Pharmacology. 73(3). 613–621. 41 indexed citations
7.
Parker, Ceth W., Julie Wolf, Augusto S. Auler, Hazel A. Barton, & John M. Senko. (2013). Microbial Reducibility of Fe(III) Phases Associated with the Genesis of Iron Ore Caves in the Iron Quadrangle, Minas Gerais, Brazil. Minerals. 3(4). 395–411. 36 indexed citations
8.
Richardson, Frank C., Geoffrey D. Young, Julie Wolf, et al.. (2012). The evaluation of E-Cadherin and vimentin as biomarkers of clinical outcomes among patients with non-small cell lung cancer treated with erlotinib as second- or third-line therapy.. PubMed. 32(2). 537–52. 40 indexed citations
9.
Hughes, Andrew, Mary O’Brien, W. Jeffrey Petty, et al.. (2009). Overcoming CYP1A1/1A2 Mediated Induction of Metabolism by Escalating Erlotinib Dose in Current Smokers. Journal of Clinical Oncology. 27(8). 1220–1226. 116 indexed citations
10.
Dragovich, Tomislav, Mark S. Huberman, Daniel D. Von Hoff, et al.. (2006). Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial. Cancer Chemotherapy and Pharmacology. 60(2). 295–303. 40 indexed citations
11.
Frohna, Paul, Jianfeng Lu, Steve Eppler, et al.. (2006). Evaluation of the Absolute Oral Bioavailability and Bioequivalence of Erlotinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in a Randomized, Crossover Study in Healthy Subjects. The Journal of Clinical Pharmacology. 46(3). 282–290. 82 indexed citations
12.
Colagiovanni, Dorothy B., et al.. (2006). Safety Assessment of 4′-Thio-β-d-Arabinofuranosylcytosine in the Beagle Dog Suggests a Drug-Induced Centrally Mediated Effect on the Hypothalamic-Pituitary-Adrenal Axis. International Journal of Toxicology. 25(2). 119–126. 2 indexed citations
13.
Hamilton, Marta, Julie Wolf, Jason Rusk, et al.. (2006). Effects of Smoking on the Pharmacokinetics of Erlotinib. Clinical Cancer Research. 12(7). 2166–2171. 240 indexed citations
14.
Patnaik, Amita, Debra L. Wood, Anthony W. Tolcher, et al.. (2006). Phase I, Pharmacokinetic, and Biological Study of Erlotinib in Combination with Paclitaxel and Carboplatin in Patients with Advanced Solid Tumors. Clinical Cancer Research. 12(24). 7406–7413. 23 indexed citations
15.
Hamilton, Marta, Julie Wolf, Jianfeng Lü, et al.. (2005). Tarceva™ (erlotinib) exposure/effects (EE) analysis from a Phase III study in advanced NSCLC: Effect of smoking on the PK of erlotinib. 65. 1451–1451. 16 indexed citations
16.
Drolet, Daniel W., J. Arly Nelson, Philip M. Zack, et al.. (2000). Pharmacokinetics and Safety of an Anti-Vascular Endothelial Growth Factor Aptamer (NX1838) Following Injection into the Vitreous Humor of Rhesus Monkeys. Pharmaceutical Research. 17(12). 1503–1510. 159 indexed citations
17.
Richardson, Frank C., Bud C. Tennant, Denny J. Meyer, et al.. (1999). An Evaluation of the Toxicities of 2' -Fluorouridine and 2'-Fluorocytidine-HCI in F344 Rats and Woodchucks (Marmota monax). Toxicologic Pathology. 27(6). 607–617. 28 indexed citations
18.
Arbisi, Paul A., et al.. (1996). Seasonal alteration in taste detection and recognition threshold in seasonal affective disorder: the proximate source of carbohydrate craving. Psychiatry Research. 59(3). 171–182. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yoshihiro Hashimoto Breakdown of academic impact, for papers by Valentina Rossi Breakdown of academic impact, for papers by H Harvey Breakdown of academic impact, for papers by Renato V. La Rocca Breakdown of academic impact, for papers by Ritva Valavaara Breakdown of academic impact, for papers by Shinji Kikuchi Breakdown of academic impact, for papers by Rosemary Chester Breakdown of academic impact, for papers by Christopher S. Hong Breakdown of academic impact, for papers by Rogelio Palomino‐Morales Breakdown of academic impact, for papers by Gunhild Keller
Rankless by CCL
2026